Login to Your Account

Tivantinib misses OS endpoint in phase III liver cancer trial

By Michael Fitzhugh
Staff Writer

Friday, February 17, 2017

The oral c-Met inhibitor tivantinib missed its primary endpoint of improving overall survival vs. placebo in a phase III hepatocellular carcinoma (HCC) study.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription